Inogen Achieves Q3 Growth Despite Consumer Sales Decline
Deal News | Nov 08, 2024 | EIN
Inogen has reported an increase in revenue for the third quarter of 2024, driven by strong demand in its B2B channels, reaching $88.8 million, a 5.8% rise year over year despite a drop in direct-to-consumer sales. The company also saw improvements in its financial metrics, including a decrease in its operating expenses and a reduction in its GAAP net loss. Viemed Healthcare posted a 17.4% revenue rise, driven by an 11% increase in ventilator and sleep therapy patients. Insulet delivered impressive results with a 25.7% revenue increase, spearheaded by its Omnipod product line, leading the market in insulin delivery systems. InfuSystem achieved an 11% revenue increase, aided by strategic partnerships, while OneroRx expanded its pharmacy services through the acquisition of EverCare locations, enhancing its presence in Missouri. Additionally, Citizens Memorial Hospital acquired Evans Drugs locations, strengthening its retail pharmacy network. Insulet's efforts to raise diabetes awareness highlight its commitment to public health.
Sectors
- Healthcare Equipment & Services
- Pharmaceuticals & Biotechnology
Geography
- United States – The majority of the companies discussed, such as Inogen, Viemed, Insulet, and OneroRx, operate primarily within various regions of the United States.
- Switzerland – PharmaSens, a company in the article, is based in Switzerland and focuses on diabetes technology.
Industry
- Healthcare Equipment & Services – This industry includes companies engaged in the sales and distribution of healthcare equipment, like Inogen's oxygen solutions, Insulet's insulin delivery systems, and InfuSystem and Viemed's respiratory care services.
- Pharmaceuticals & Biotechnology – This industry covers companies involved in the research, development, and distribution of drugs, such as OneroRx and Citizens Memorial Hospital's pharmacy acquisitions and services.
Financials
- $88.8 million – Inogen's Q3 2024 total revenue.
- 46.5% – Inogen's Q3 2024 total gross margin.
- $6 million – Inogen's Q3 2024 GAAP net loss.
- $58 million – Viemed Healthcare's Q3 2024 revenue.
- $543.9 million – Insulet's Q3 2023 total revenue.
- $35.3 million – InfuSystem's Q3 2024 total revenue.
- $7.9 million – InfuSystem's Q3 2024 Adjusted EBITDA.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Inogen | Company | Target | A healthcare company that specializes in respiratory products and reported Q3 financial results. |
| Viemed Healthcare | Company | Participant | A healthcare service provider focusing on respiratory care that reported increased revenue and patient counts. |
| Insulet | Company | Participant | Manufacturer of Omnipod insulin delivery systems, reporting strong revenue growth. |
| InfuSystem Holdings | Company | Participant | Healthcare company providing infusion pumps and related services, reporting revenue growth and new strategic partnerships. |
| OneroRx | Company | Bidding Company | A pharmacy service provider expanding its presence through acquisitions. |
| EverCare Pharmacy | Company | Selling Company | Pharmacy chain acquired by OneroRx. |
| Citizens Memorial Hospital | Company | Bidding Company | A hospital expanding its pharmacy services through acquisitions. |
| Evans Drugs | Company | Selling Company | Pharmacy chain being acquired by Citizens Memorial Hospital. |
| PharmaSens | Company | Participant | A Swiss company focused on developing insulin delivery technology. |